Inion Oy Share Discussion Threads

[mikey34] 30/4/2009 17:01

irene,

Agreed on all points.

[irenekent] 30/4/2009 12:56

This is a sorry state of affairs. Considering the value of the products they have created it seems outrageous that this can be allowed to go to the wall. I would have thought that Smith & Nephew or Glaxo could have picked this up. And what about 3i? Maybe the Finnish government could help. The world needs these sorts of innovative products. Maybe they will be saved at the last minute, but I doubt it.

[mmamuk2] 16/8/2008 22:37

Volumes have been low of late, so how has the threshold been crossed ?

[pre] 15/8/2008 08:14

Nice news this am...barclays now hold some 9.2M shares and looks like they have crossed the threshold and upped their stake to 12.15% by moving 5% to 10% threshold as per the rns this morning..don't think this has been spotted yet. Dyor etc:-))

[pre] 11/8/2008 07:28

EGM on wednesday ...be interesting to see what developments are announced by the company...

[pre] 11/8/2008 07:22

Out-licensing agreement (Inion Oy)




RNS Number : 0340B
Inion Oy
11 August 2008





Inion Oy
("Inion or the "Company")

Inion licenses bioactive bone regrowth technology
to US company Curative Biosciences Inc.

Tampere, Finland and Guildford, UK. 11 August 2008, Inion (LSE: IIN.L), today announces
the signature of an out-licensing agreement with
US company, Curative Biosciences Inc. (Waltham, MA), covering certain of its novel bioactive
technologies for the promotion of bone regrowth
and repair when treating patients undergoing orthopaedic surgical procedures. Under the terms
of the licensing agreement, Curative
Bioscience Inc. will pay to Inion a small upfront fee, development and sales milestones of up
to US$2,025,000 and royalties on revenues
generated from any products developed using the technology.

The licensed technology is based on the use of N,N-dimethylacetamide (DMA) and its
pharmaceutically acceptable salts and prodrugs,
either alone or incorporated in resorbable polymer structures (such as plates, membranes and
screws) for implantation in patients. Patent
applications covering this technology in the UK and internationally have been filed and are
pending.

Chris Lee, Inion's CEO, said: "DMA was discovered to have bioactive properties in
promoting bone repair and regrowth through research
work undertaken at our Cambridge facility prior to its closing last year. Inion, however, is
no longer pursuing early stage development work
in this area as it focuses on the commercialisation of its existing product portfolio for
spinal surgery and orthopaedic trauma. By
out-licensing non-core intellectual property and technologies, such as DMA, we seek to realise
the value resulting from our research through
companies more focused in these areas."


-ends-

For further information, please contact:

Inion Oy Tel: [phone]
Chris Lee, Chief Executive
Officer
Julien Cotta, Chief
Financial Officer

Citigate Dewe Rogerson Tel: [phone]
Mark Swallow / David Dible

About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative
biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials,
with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials
that promote bone healing and accelerate
patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing
Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and USA, and its head office, R&D and production facilities are
in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other
than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business
strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's
products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes",
"estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results,
performance or achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous
assumptions regarding the Group's present and future business strategies and the environment in
which the Group
will operate in the future. Among the important factors that could cause the Group's actual
results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding
requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These
forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations
with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to
rely on any forward-looking statement.


This information is provided by RNS
The company news service from the London Stock Exchange

END

[pre] 11/8/2008 07:13

nice...rns out this am re:out-licensing agreement....looks like this is yet to be spotted today....

[pre] 07/8/2008 07:15

EGM next week....more positive news on the way? All indicators blue this am....well undervalued imo....

[mikey34] 06/8/2008 07:59

PRE,

Agreed.The mkt has battered co's with small mkt caps and profits not in the bag now.But this co has excellent prospects long term for the patient investor IMO.

[pre] 06/8/2008 07:11

patience will be rewarded...looks like someone is in the know as you say irenekent...bodes well considering this is well undervalued imo, dyor etc:-)

[sheilae] 05/8/2008 16:12

Is there a new boss here?

[irenekent] 05/8/2008 15:44

Big jump today - as usual someone knows something in advance of an announcement I would bet and all before the new boss is installed.

[hyper al] 15/7/2008 20:52

The market is looking for real money, not hopes!

This is the trouble with biotechnology type stocks, don't get me wrong, I appreciate many are doing a lot of good R & D, but that does not bring the money in. I'm a big RENE fan, when talking about their research, but I am VERY VERY cautious about investing in them.

To be honest I can't see how today's news can impact on the share price at the companies current Market Cap. The total market potential is just so small and you have still got to compete with the current suppliers.

[mikey34] 15/7/2008 20:44

pre,

I agree.... the wider mkt is the problem today.

,

[pre] 15/7/2008 07:20

This looks well undervalued here imo....excellent pre-close trading statement following now by a cracking rns re:regulatory approval...

[pre] 15/7/2008 07:09

Wonder how much this is worth to IIN....this will open up other markets imo, with the US already opening up imo:-))

Found it!

It estimates that the US market for these procedures is worth
approximately 318 million euro and 32 million euro, respectively.

[pre] 15/7/2008 07:06

Cracking RNS....regulatory approval obtained:-)))))))


Regulatory Approval (Inion Oy)




RNS Number : 0510Z
Inion Oy
15 July 2008


Inion Oy
("Inion or the "Company")


Inion receives 510(k) marketing clearance to sell its biodegradable graft containment
systems in the USA for spinal fusion procedures


Tampere, Finland and Guildford, UK. 15 July 2008, Inion (LSE: IIN.L), the company focused
on the development and commercialisation of
novel biodegradable medical implants, today announces it has received 510(k) marketing
clearance from the US Food and Drug Administration
(FDA) for its biodegradable graft containment systems for spinal fusion procedures.

The US marketing clearance has been received for the Inion S-1* Anterior Cervical Fusion
System, the Inion S-1* double-level plate and
the Inion S-2* Anterior Thoraco-Lumbar Fusion System. These systems consist of biodegradable
plates and screws, which are designed for bone
graft containment in spinal fusion procedures. Such procedures are carried out as a treatment
for a range of spinal conditions including
ruptures and displacement of inter-vertebral discs. Inion's S-1* and Inion S-2* graft
containment systems include implants intended for use
along the entire length of the spine in conjunction with traditional rigid fixation.

These new graft containment systems also incorporate a radiographic marker to the edges of
the plates and to the tips of screws. These
markers enable surgeons to view the position of the implants in post-operative x-ray without
interfering with their assessment of the site
of surgery and its healing progress.

More than 183,000 cervical plating procedures (Ref. 1) and more than 10,000 anterior
thoraco-lumbar plating procedures (Ref. 2) were
performed in 2006 in the USA. The US market for these procedures was worth approximately
EUR318 million and EUR32 million, respectively. The
number of spinal plating procedures has since grown at an annual rate of approximately 30%.

Inion's biodegradable implants offer significant clinical benefits over traditional metal
materials, primarily in that they slowly and
completely degrade over time into carbon dioxide and water, which are absorbed into the body.

The Inion S-1* and Inion S-2* graft containment systems received CE Mark marketing
clearance in Europe in August 2007 and September
2007, respectively.

Chris Lee, Inion's CEO, said: "The US marketing clearance for our biodegradable spine
products is great news. We are already seeing
increased uptake of this important product line in Europe where awareness and acceptance of
the clinical benefits of biodegradable medical
implants is rapidly growing among surgeons, who are adopting this technology into their
practice. Our aim now is to push these new
biodegradable products aggressively into the US spine market where we believe it will make an
attractive alternative to traditional metal
plates and a strong driver of value for the Company."


References
1. Spinemarket, Inc: US spinal implant market: Cervical plate analysis. 2007
2. Spinemarket, Inc: US spinal implant market: Anterior lumbar plating analysis. 2007

-ends-

For further information, please contact:

Inion Oy Tel: [phone]
Chris Lee, Chief
Executive Officer
Julien Cotta, Chief
Financial Officer

Citigate Dewe Rogerson Tel: [phone]
Mark Swallow / David
Dible

About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative
biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials,
with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate
patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing
Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and USA, and its head office, R&D and production facilities are
in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other
than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business
strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's
products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes",
"estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results,
performance or achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous
assumptions regarding the Group's present and future business strategies and the environment in
which the Group
will operate in the future. Among the important factors that could cause the Group's actual
results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding
requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These
forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations
with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to
rely on any forward-looking statement.


This information is provided by RNS
The company news service from the London Stock Exchange

END

REAZGGMNGDLGRZZ

[pre] 14/7/2008 19:39

Interesting extract from todays rns....not long to go before the results in August...this little tiddler looks to have been overlooked by the market in recent weeks but no doubt management appear very confident with the business as it currently stands:

'....Ian Paling said: "Inion has undergone many important changes over the past two years and I
believe is in an excellent position to
capitalise on the innovative technology and products it has developed. I am looking forward to
working with the Company's Board and
management team and believe that my experiences in growing Corin and other companies will
allow me to make a very positive contribution to
the future growth of this business."

Chris Lee, Inion CEO, said: "We strongly believe that Inion has turned an important corner
following a period of significant change that
saw the Company completely refocus and restructure itself in order to better leverage its
unique biomaterial technologies to realise its
long-term value potential. Goran played a significant role in this process as well as bringing
important discipline to the management of the
organisation and, on behalf of the management team and Board, I would like to thank him and
wish him every success in the future with his
other business interests.

[pre] 07/7/2008 19:09

mikey34...couldn't agree more....looks like its heading back up from here..reckon the pre close trading statement was positive imo and took the market by surprise....i'm expecing this to move back up from here over the coming days and weeks....

[mikey34] 07/7/2008 13:36

pre,

I am at a loss(literally) to explain why this has fallen so far.

[pre] 07/7/2008 07:34

mm's on the offer...tick up coming?

[pre] 07/7/2008 07:13

Let's see what today brings....a bullish trading update from IIN...we should see this advance further from here imo...

[pre] 04/7/2008 08:32

imo, this fall looks well overdone over the past few weeks....today IIN have announced a bulllish update and are showing increasing strength in overseas market which bodes well:-)

[pre] 04/7/2008 07:24

Pre-close Trading Update (Inion Oy)




RNS Number : 3088Y
Inion Oy
04 July 2008


Inion Oy
("Inion or the "Company")

Pre-close Trading Update

Tampere, Finland and Guildford, UK. 4 July 2008, Inion (LSE: IIN.L), the company focused
on the development and commercialisation of
novel biodegradable medical implants, today provides an update on 2008 trading, ahead of its
half-yearly results announcement expected in
August 2008.

Based on the unaudited figures for the six months to 30 June 2008, the Directors
anticipate that revenues for the period will be
approximately EUR2.6 million, up 12% on the corresponding period in 2007. Invoiced sales of
EUR1.8 million for the second quarter were 115%
higher than in the first quarter of 2008, and 34% higher than in the corresponding period in
2007. These positive trends lead us to believe
that Inion is on track to meet current market expectations of circa EUR7.0 million in sales
for the full year 2008.

Significantly, within these growth figures there is evidence to suggest Inion is starting
to gain traction in the important US market.

Chris Lee, Inion's CEO, said: "We continue to make good progress with executing our
commercial strategy and are pleased to see sales
growing strongly across our focused market segments. This uplift in sales is as a result of
our commercial teams in these areas becoming
more effective and an increasing awareness and acceptance among surgeons of the clinical
benefits our biodegradable products can bring."


-ends-

For further information, please contact:

Inion Oy Tel: [phone]
Chris Lee, Chief
Executive Officer
Julien Cotta, Chief
Financial Officer

Citigate Dewe Rogerson Tel: [phone]
Mark Swallow / David
Dible

About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments.

Inion's core expertise and technology lies in the design and manufacture of innovative
biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion Optima* family of biomaterials,
with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation

Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials
that promote bone healing and accelerate
patient rehabilitation.

Inion was incorporated in early 2000 and listed on the Official List of the UK Listing
Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and USA, and its head office, R&D and production facilities are
in Tampere, Finland.

This announcement includes "forward-looking statements" which include all statements other
than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business
strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's
products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes",
"estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative
thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results,
performance or achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous
assumptions regarding the Group's present and future business strategies and the environment in
which the Group
will operate in the future. Among the important factors that could cause the Group's actual
results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding
requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These
forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations
with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these
factors, prospective investors are cautioned not to
rely on any forward-looking statement.


This information is provided by RNS
The company news service from the London Stock Exchange

END

TSTFKNKDOBKDQOK

[pre] 04/7/2008 07:22

Nice positive pre-close trading update....fall was overdone here by the looks of things..